Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000425165 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Online course on vaccinating people with HIV/AIDS - effectiveness in the knowledge of nursing professionals.
Rev Lat Am Enfermagem
August 2024
Universidade de São Paulo, Escola de Enfermagem de Ribeirão Preto, PAHO/WHO Collaborating Centre for Nursing Research Development, Ribeirão Preto, SP, Brazil.
Objective: analyzing the effectiveness of an educational intervention on the knowledge of nursing professionals regarding the immunization of people with the human immunodeficiency virus.
Method: a quasi-experimental study evaluated professionals' knowledge through a knowledge test applied before and after the development of an online training course. The data was analyzed using frequency, median, mean, standard deviation, and association tests.
Current status of the small molecule anti-HIV drugs in the pipeline or recently approved.
Bioorg Med Chem
September 2024
Faculty of Veterinary Science, University of Nyala, P.O. Box: 155, Nyala, Sudan; Nanotechnology in Veterinary Medicine (NanoVet) Research Group, Faculty of Veterinary Medicine, University Malaysia Kelantan, Kelantan 16100, Pengkalan Chepa, Malaysia.
Article Synopsis
- Human Immunodeficiency Virus (HIV) causes Acquired Immunodeficiency Syndrome (AIDS) with significant health risks, especially in low- and middle-income countries due to increasing drug resistance and treatment challenges.
- Progress is being made in developing new antiretroviral (ARV) drugs that target various HIV components and mechanisms, currently undergoing clinical trials, with specific compounds being discussed in terms of their efficacy and safety.
- Continuous efforts are vital for advancing the discovery of innovative ARV treatments to mitigate drug resistance and improve patient outcomes, as there is currently no cure or vaccine for HIV.
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.
Lancet Infect Dis
November 2024
Janssen Research & Development, Titusville, NJ, USA.
Background: HIV type 1 (HIV-1) remains a global health concern, with the greatest burden in sub-Saharan Africa. Despite 40 years of research, no vaccine candidate has shown durable and protective efficacy against HIV-1 acquisition. Although pre-exposure prophylaxis in groups with high vulnerability can be very effective, barriers to its use, such as perceived low acquisition risk, fear of stigma, and concerns about side-effects, remain.
View Article and Find Full Text PDFCase 324: CHANTER Syndrome.
Radiology
April 2024
From the Department of Diagnostic Radiology and Nuclear Medicine, Rush University Medical Center, 1653 W Congress Pkwy, Chicago, IL 60612.
A 69-year-old right-handed man with a history of substance use disorder, hypertension, and diabetes presented to the emergency department in an unresponsive state. Upon examination, apart from tachycardia (heart rate, 108 beats per minute), vital signs were within normal ranges (blood pressure, 134/102 mm Hg; temperature, 97.9 ºF (36.
View Article and Find Full Text PDFEvaluation of the VioOne HIV profile supplemental assay.
J Clin Microbiol
February 2024
Department of Pathology and Laboratory Medicine, UNC-Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
HIV is an ongoing global epidemic with estimates of more than a million new infections occurring annually. To combat viral spread, continuous innovations in areas including testing and treatment are necessary. In the United States, the Centers for Disease Control and Prevention recommend that laboratories follow an HIV testing algorithm that first uses a US Food and Drug Administration approved immunoassay to detect antibodies to HIV-1 or HIV-2 as well as HIV-1 p24 antigen in serum or plasma samples.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!